Tomasz Kubiatowski

St. John's Cancer Center
Lublin, LU, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

HPA axis function during adjunctive high-dose dexamethasone use in chemotherapy: a prospective pilot study.

HPA axis function during adjunctive high-dose dexamethasone use in chemotherapy: a prospective pilot study.

Journal: Frontiers in endocrinology

Published: February 12, 2026

Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.

Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.

Journal: Przeglad menopauzalny = Menopause review

Published: August 24, 2025

A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts - cardiologists and oncologists.

A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts - cardiologists and oncologists.

Journal: Kardiologia polska

Published: August 04, 2023

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.

Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.

Journal: Melanoma research

Published: April 04, 2023

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Journal: Targeted oncology

Published: February 19, 2023

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland.

Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland.

Journal: Frontiers in oncology

Published: November 26, 2022

RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.

RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.

Journal: Cancers

Published: September 06, 2022

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients.

Journal: Cancers

Published: April 02, 2022

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.

Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.

Journal: The Journal of dermatological treatment

Published: May 31, 2021

First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.

First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland.

Journal: Immunotherapy

Published: December 23, 2020

Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients.

Journal: Melanoma research

Published: November 09, 2020

Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.

Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.

Journal: Oncology letters

Published: November 04, 2020

Showing 1-12 of 25

Last Updated: 09/26/2026